ReviewFrontiers in medicine2020
Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis.BMC infectious diseases · 2023Pooled it
- Borrelia burgdorferi disrupts gut barrier functions and microbiota-antibody interactions.The Journal of experimental medicine · 2026Article
- Mostly getting along -Borrelia burgdorferi and its manipulation of the host immune system.ImmunoHorizons · 2026Review
- Antiphospholipid antibodies in acute and post-treatment Lyme disease.Infection and immunity · 2026Article
- Post-Treatment Lyme Disease Syndrome in Six European Countries Using Data from the Burden of Lyme Disease (BOLD) Study.Pathogens (Basel, Switzerland) · 2026Article
- Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study.Pathogens (Basel, Switzerland) · 2026Article
- Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.Brain : a journal of neurology · 2026Review
- Epidemiology, diagnosis and emerging therapies for Lyme disease of the Northern Hemisphere.International journal of emergency medicine · 2026Review
- Infection-Triggered Immune Dysregulation and Immunopathology in Lyme Disease: Mechanisms and Clinical Implications.Journal of clinical medicine · 2026Review
- Characterization ofMicroorganisms · 2026Article
- Multiplexed single-tier immunoassay for improved Lyme disease diagnosis across all disease stages.Research square · 2026Article
- Sex and menopause-based differences in presentation of early Lyme disease: A prospective cohort study.Clinical and experimental medicine · 2026Article
- Probable European-profileFrontiers in medicine · 2026Article
- Evidence-domain translation in the Lyme disease controversy over persistent post-treatment symptoms.Frontiers in cellular and infection microbiology · 2026Article
- Peptidoglycan architecture dictates protein interactions, tissue tropism, and arthritis in the Lyme disease spirochete Borrelia burgdorferi.PLoS pathogens · 2026Article
- Autonomic Symptoms in Post-Treatment Lyme Disease: Insights From the COMPASS-31 and the 10-Minute Active Stand Test.Mayo Clinic proceedings. Innovations, quality & outcomes · 2025Article
- Early brain changes in Lyme disease are associated with clinical outcomes.Brain, behavior, & immunity - health · 2025Article
- Temporal Dynamic Interplay of Mouse Proteome during ProtozoanJournal of proteome research · 2025Article
- Cerebrospinal fluid protein profiling of inflammatory and neurobiological markers in Lyme neuroborreliosis.Scientific reports · 2025Article
- Diagnostic and Therapeutic Challenges in Lyme Disease and Co-Infections: Unraveling Neuropsychiatric and Neurological Complexities-A Comprehensive Case Series Analysis.Integrative medicine (Encinitas, Calif.) · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has long been observed in clinical practice that a subset of patients with Lyme disease report a constellation of symptoms such as fatigue, cognitive difficulties, and musculoskeletal pain, which may last for a significant period of time. These symptoms, which can range from mild to severe, have been reported throughout the literature in both prospective and population-based studies in Lyme disease endemic regions. The etiology of these symptoms is unknown, however several illness-causing mechanisms have been hypothesized, including microbial persistence, host immune dysregulation through inflammatory or secondary autoimmune pathways, or altered neural networks, as in central sensitization. Evaluation and characterization of persistent symptoms in Lyme disease is complicated by potential independent, repeat exposures to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.